Carrolee Barlow, M.D., Ph.D., former Chief Executive Officer of the Parkinson’s Institute and Clinical Center and an author on the study said, “The Parkinson’s Institute and Clinical Center is at the forefront of evaluating new technologies and therapeutics, and is committed to providing the highest quality of care for people with movement disorders. The wearable PKG technology provides objective measurements which allow us to further deliver the highly individualized care that a patient deserves.”
Currently, it is difficult to track a patient’s motor symptoms when the patient is at home. Global Kinetics’ PKG is the first FDA-cleared technology to provide continuous quantitative data on movement disorder symptoms including tremor, bradykinesia (slow movement) and dyskinesia (abnormal or impaired movement) in a non-clinical setting. The wearable technology is worn at home by patients for several days to help objectively monitor motor symptoms and the information is then transmitted to their physician for review during their next clinical visit.
The study, reported in the Journal of Parkinson’s Disease, was conducted at the Parkinson’s Institute and Clinical Center from December 2015 through July 2016. It was comprised of a survey completed by four movement disorder specialists to whom PKG data was available for four categories of patients: patients visiting the clinic for the first time, patients with fluctuations in Parkinson’s symptoms, patients with an unclear Parkinson’s symptom history and patients considering advanced therapy. For each patient visit, the survey assessed whether the PKG provided additional information beyond what could be gathered through physician examination and patient-reported symptoms. An evaluation of the impact of the additional information on changes to clinical management was assessed.
Of the 112 surveys conducted in the study, 41% indicated that the PKG provided additional information to the physician. Of these surveys, 78% showed that the data resulted in changes to the patient’s treatment plan. The most common new piece of information from the PKG resulting in treatment changes was precise information on when the patient was not adequately treated, referred to as “daily OFF times” (50%).
John Schellhorn, CEO of Global Kinetics Corporation said, “These results demonstrate the real-world clinical benefits that PKG can provide to patients and clinicians in their continuing effort to optimize Parkinson’s therapy, and manage symptoms effectively. In the absence of standardized objective measures for assessing and managing PD, we believe that PKG has the potential to transform the care and outcomes of patients living with the daily challenges of this disease. The results of this study support the use of PKG as an important tool for individualizing therapy to best meet each patient’s unique needs.”